In this phase @b , multicentre , randomized , open-label study , patients with moderate-to-severe plaque psoriasis received etanercept @ mg BIW for @ weeks , and then were randomized to etanercept @ mg BIW or @ mg QW plus topical agent as needed to achieve static physician global assessment ( sPGA ) status of clear for @ weeks .